Other Events ·
Reports 120% growth in LYMPHIR unit sales to U.S. wholesalers, reaching 792 units for fiscal Q4
CTXRCitius Pharmaceuticals, Inc.
Citius Pharmaceuticals reported preliminary, unaudited data showing a 120% increase in LYMPHIR unit sales to U.S. wholesalers during the fiscal fourth quarter ended September 30, 2026, rising from 360 units in the prior quarter to 792 units. Prescribing centers ordered 950 vials during the period, and the number of institutions ordering the drug increased to 54 from 44 as of mid-August. The company attributes this growth to expanded commercial coverage achieved in August and expects momentum to continue into fiscal 2027. Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing critical care products.